Effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis

doi:10.12092/j.issn.1009-2501.2018.06.016

Abstract

Abstract:

AIM: To investigate the effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis type. METHODS: Sixty cases of lung cancer patients with Qi deficiency and blood stasis were divided into observation group and control group. The control group was treated with routine nutritional support. The observation group was given Buyanghuanwu decoction on the basis of the control group. The KPS score was recorded to assess the quality of life of the patients. Symptoms of Chinese medicine were evaluated by TCM symptom score. Blood rheology indexes (whole blood viscosity, plasma viscosity, hematocrit, fibrinogen and platelet) were detected before and after treatment of the two groups. The levels of serum tPA and PAI-1 were detected before and after treatment 7, 14, 28 d in two groups. The incidence of pulmonary embolism in the two groups was recorded during the treatment.RESULTS:The curative effect of the observation group was significantly higher than that of the control group. The difference was statistically significant (P<0.05). The curative effect of TCM symptom score in the observation group was significantly higher than that in the control group. The difference was statistically significant (P<0.05). The whole blood viscosity, plasma viscosity, hematocrit, fibrinogen and platelets were significantly decreased after treatment in the observation group. And the above indexes were significantly lower than that of the control group. The difference was statistically significant (P<0.05). After 28 d of treatment, the tPA in the observation group was significantly higher than that of the control group. PAI-1 was significantly lower than that of the control group. The difference was statistically significant (P<0.05). The incidence of pulmonary embolism in the observation group was lower than that in the control group. But the difference was not statistically significant (P>0.05). CONCLUSION: Buyanghuanwu decoction can significantly improve the hypercoagulable state of patients with Qi deficiency and blood stasis type lung cancer, and improve the quality of life of patients.

Key words: Buyanghuanwu decoction, Qi deficiency and blood stasis type, lung cancer, hypercoagulable state

CLC Number:

R734.2

ZHENG Qingxiu，XU Xiaoxiao，LIU Gang，MA Xiaodong. Effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 694-699.

References

［1］韩啸东, 张侠, 刘畅,等. 非小细胞肺癌患者血液高凝状态的临床调查［J］. 现代生物医学进展, 2015, 15(5):882-886.
［2］何佩珊, 杨公博, 潘国凤,等. 老年非小细胞肺癌患者围手术期证型变化及防治策略［J］. 华中医药杂志, 2017, 32(3):1057-1059.
［3］张红, 尹秀东, 李祥. 补阳还五汤加味配合头部伽玛刀治疗气虚血瘀型肺癌脑转移的临床观察［J］. 中医药导报, 2017, 23(2):49-50.
［4］支修益，吴一龙，马胜林，等.原发性肺癌诊疗规范(2011版)［J］.中国肺癌杂志，2012，15(12)：677-688.
［5］Detterheck FC, Boffa DJ,fanoue LT.fhe new lung cancer staging system［J］.Chest,2009,136(1):260-271.
［6］国家食品药品监督管理总局.中药新药临床研究指导原则(试行)［S］.北京:中国医药科学出版社，2002:216-221.
［7］孙燕.临床肿瘤内科手册第三版［M］. 北京:人民卫生出版社, 1987:53-54.
［8］王静, 张侠. 恶性肿瘤患者高凝状态的危险因素、发生机制及实验室检测［J］.检验医学与临床, 2015, 12(15):2284-2287.
［9］闫绍辉, 王栋, 李湘红,等.恶性肿瘤患者高凝状态与血栓形成的临床研究［J］.中国肿瘤临床与康复, 2014, 21(5):542-544.
［10］韩燕, 杨国旺, 王笑民. 晚期非小细胞肺癌中医证候分布及组合规律文献研究［J］. 北京中医药, 2014, 33(3):175-178.
［11］逄艳, 张芳. 补阳还五汤改善晚期肺癌高凝状态的临床研究［J］. 云南中医中药杂志, 2017, 38(7):33-34.
［12］王冬梅, 施怡, 姚新颖,等. 益气活血膏方与补阳还五汤颗粒对气虚血瘀证患者血液流变学影响比较［J］. 世界中医药, 2014, 9(10):1296-1297.
［13］黄兴, 李艳芬, 寇冠军,等. 补阳还五汤抗动脉粥样硬化作用机制研究进展［J］. 中华中医药杂志, 2017, 32(3):1187-1190.
［14］李鸿波, 许启霞. 晚期肺癌患者凝血纤溶系统的变化及化疗对其的影响［J］. 肿瘤防治研究, 2014, 41(7):766-770.
［15］刘明, 周承志, 欧阳铭. 尿激酶型纤溶酶原激活物抑制剂1参与非小细胞肺癌的侵袭与转移［J］. 国际呼吸杂志, 2015, 35(12):881-885.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[6]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[7]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[8]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[9]	WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
[10]	ZHAO Ziwen, FAN Fangtian, JIANG Zhijun. Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 353-360.
[11]	CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
[12]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[13]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[14]	WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
[15]	YANG Guoliang, HU Dandan, XU Yikai, LOU Liming. Yiqi Huoxue decoction inhibits malignant biological behavior of human lung cancer cells via the miR-21/PTEN signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 512-518.